NASDAQ:KURA - Kura Oncology Stock Price, Forecast & News

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Kura Oncology Inc (NASDAQ:KURA) announced its earnings results on Tuesday, November, 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. View Kura Oncology's Earnings History.

Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Kura Oncology.

8 analysts have issued twelve-month target prices for Kura Oncology's shares. Their forecasts range from $22.00 to $30.00. On average, they expect Kura Oncology's share price to reach $26.83 in the next year. This suggests a possible upside of 129.9% from the stock's current price. View Analyst Price Targets for Kura Oncology.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.

News articles about KURA stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kura Oncology earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Kura Oncology.

Kura Oncology saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 2,000,000 shares, a decline of 10.7% from the December 31st total of 2,240,000 shares. Based on an average trading volume of 272,100 shares, the short-interest ratio is presently 7.4 days. Approximately 4.9% of the shares of the company are short sold. View Kura Oncology's Current Options Chain.

Some companies that are related to Kura Oncology include Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Epizyme (EPZM), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Cambrex (CBM), Xencor (XNCR), Ironwood Pharmaceuticals (IRWD), Principia Biopharma (PRNB), Zymeworks (ZYME), Pacira Biosciences (PCRX), Insmed (INSM), Akcea Therapeutics (AKCA) and Arvinas (ARVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX) and Amicus Therapeutics (FOLD).

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KURA stock can currently be purchased for approximately $11.67.

Kura Oncology has a market capitalization of $528.77 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.

The official website for Kura Oncology is http://www.kuraoncology.com/.

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]